Immune Activation Anti-Cancer Antiviral Gut Health Metabolic Patents
Home›Topics› Metabolic & Cardiovascular
Research Topic

Metabolic & Cardiovascular Research

Research on Aureobasidium pullulans beta glucan and metabolic health: cholesterol modulation, blood glucose effects, anti-atherosclerotic mechanisms, and cardiovascular risk factors.

20+ Studies Cholesterol Reduction Atherosclerosis Model Blood Glucose Effects
Direct Answer

Research documents metabolic effects of Aureobasidium pullulans beta glucan including LDL cholesterol reduction in animal and human studies, blood glucose modulation in diabetic animal models, and anti-atherosclerotic effects in apolipoprotein E knockout (ApoE KO) mouse models. Unlike oat beta glucan (FDA-approved for cholesterol via viscosity), Aureobasidium beta glucan’s mechanisms may involve immune-mediated pathways in addition to direct metabolic effects.

Metabolic Mechanisms

Metabolic Pathways in Beta Glucan Research

Cholesterol Reduction

Animal studies document reductions in total cholesterol and LDL following oral Aureobasidium beta glucan supplementation. Proposed mechanisms include bile acid sequestration (similar to oat β-glucan) and hepatic cholesterol metabolism modulation via immune signaling.

Blood Glucose Modulation

Studies in diabetic animal models document blood glucose-lowering effects following beta glucan administration. Mechanisms under investigation include delayed gastric emptying, modulation of glucose transporter expression, and anti-inflammatory effects in pancreatic tissue via macrophage polarization.

Anti-Atherosclerotic Effects

ApoE knockout mouse studies — a standard model for atherosclerosis research — show reduced plaque formation and macrophage foam cell development in beta glucan-treated groups. Anti-inflammatory macrophage polarization (M2) may reduce vascular inflammation contributing to plaque development.

Anti-Inflammatory Metabolic Effects

Chronic low-grade inflammation is a driver of metabolic syndrome, type 2 diabetes, and cardiovascular disease. Beta glucan’s immune-modulating effects — particularly macrophage polarization toward anti-inflammatory phenotypes in some studies — may indirectly benefit metabolic parameters.

Key Studies

Metabolic Research

Selected peer-reviewed studies on Aureobasidium pullulans beta glucan and metabolic/cardiovascular effects.

In Vivo
In Vivo: Anti-Atherosclerotic Effects in ApoE Knockout Mouse Model
Oral beta glucan supplementation in ApoE KO mice significantly reduced aortic plaque area. Macrophage foam cell count in plaques decreased. Plasma LDL was reduced vs. untreated controls. Published in a peer-reviewed atherosclerosis journal.
Atherosclerosis · Indexed in Research Archive
In Vivo
In Vivo: Blood Glucose and Lipid Modulation in Diabetic Animal Model
Oral beta glucan significantly reduced fasting blood glucose and lipid markers in streptozotocin-induced diabetic animal models. Triglycerides and total cholesterol also reduced. Pancreatic insulin-positive cell count increased vs. control.
Journal of Nutritional Science · DOI-verified
RCT
Pilot RCT: Aureobasidium Beta Glucan and Lipid Profile in Adults with Elevated LDL
A double-blind RCT in adults with elevated LDL documented statistically significant reductions in LDL-C and total cholesterol vs. placebo. No significant change in HDL or triglycerides was reported.
Lipids in Health and Disease · Indexed in Research Archive
View All Metabolic Studies
Common Questions

Metabolic FAQ

Both types have documented cholesterol-reducing effects, but through potentially different mechanisms. Oat beta glucan (β-1,3/1,4) reduces cholesterol primarily through gut viscosity and bile acid sequestration. Aureobasidium beta glucan (β-1,3/1,6) studies show cholesterol reduction in animal and pilot human studies, with additional immune-mediated anti-inflammatory pathways proposed. Oat beta glucan has FDA health claim status for cholesterol; Aureobasidium does not.
Animal studies in diabetic models (streptozotocin-induced) show blood glucose reduction and lipid improvements. Human clinical trials specifically in diabetic patients are limited — the evidence base is primarily preclinical. Consult a physician before use if you have diabetes, as beta glucan may interact with blood glucose management.
The ApoE knockout (ApoE KO) mouse is a standard laboratory model for atherosclerosis research. These mice develop elevated LDL and spontaneous plaque formation mimicking human atherosclerosis. Studies in ApoE KO mice are considered strong preclinical evidence for anti-atherosclerotic interventions before human trials.

Browse All Metabolic Studies

20+ indexed studies with abstracts, AI summaries, DOI links, and PMID references.

Open Research Archive